Expectation still seems to be for approval this year. The complication with the dose seems to be the delaying factor.
The higher dose has sufficient efficacy for approval but the Lancet paper looked pretty convincing that the lower dose was near certain more efficacious. The dataset was however very small for the lower dose.
I've heard (insider gossip only) that a further cut of data has been submitted, which would make sense and explain the delay. If true, it must be consistent with the earlier data, or they'd be obliged to make it public. Events will be coming through fast now given the extent of the second wave.
It's worth putting this "delay" in context. So far it's been under review for 21 days. A normal review takes 18 months!
It's also worth considering the key part of the efficacy data: there was not a single case of severe disease on any dose in the trial (10 severe cases on the placebo). So regardless of the headlines on % efficacy, it's clear that mass vaccination with this would stop the pandemic dead as a public health issue.
If it is approved, we can, I think, be hopeful of near normality for summer next year. If not, it will take a lot longer, and be dependent on supply and logistics for the harder to deliver pfizer, moderna jabs.